2',2',2'-trichloroethyl 5-bromopentanoate | 68726-90-9

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: 2',2',2'-trichloroethyl 5-bromopentanoate
• 英文别名: 2,2,2-Trichloroethyl 5-bromopentanoate
• CAS: 68726-90-9
• 化学式: C₇H₁₀BrCl₃O₂
• 分子量: 312.418
• InChiKey: HFTAKVJPTFXSBD-UHFFFAOYSA-N

物化性质

• 沸点：
  351.3±42.0 °C(Predicted)
• 密度：
  1.602±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  13
• 可旋转键数：
  6
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2',2',2'-trichloroethyl 5-bromopentanoate 在 四(三苯基膦)钯 吡啶 、 disodium hydrogenphosphate 、 sodium amalgam 、 氯化亚砜 、 四甲基醋酸铵 、 sodium hydride 、 溶剂黄146 、 1,2-双(二苯基膦)乙烷 、 锌 作用下， 以 四氢呋喃 、 六甲基磷酰三胺 、 乙醚 、 乙醇 、 二甲基亚砜 、 N,N-二甲基甲酰胺 为溶剂， 反应 40.25h， 生成 recifeiolide
  参考文献：
  名称：

  Cyclization catalyzed by palladium(0). Initial studies and macrolide formation

  摘要：

  DOI：

  10.1021/ja00534a030
• 作为产物：
  描述：

  5-溴戊酸 在 草酰氯 、 N,N-二甲基甲酰胺 作用下， 以 二氯甲烷 为溶剂， 反应 20.0h， 生成 2',2',2'-trichloroethyl 5-bromopentanoate
  参考文献：
  名称：

  Unsymmetrical DNA Cross-Linking Agents:  Combination of the CBI and PBD Pharmacophores

  摘要：

  A set of 10 compounds, each combining the seco-1,2,9,9a-tetrahydrocyclopropa[c]benz[e]indol-4-one (seco-CBI) and pyrrolo[2,1-c][1,4]benzodiazepine (PBD) pharmacophores, was designed and prepared. These compounds were anticipated to cross-link between N3 of adenine and N2 of guanine in the minor groove of DNA. The compounds, which differ in the chain length separating the two alkylation subunits, and the configuration of the CBI portion, showed great variation in cellular toxicity (over 4 orders of magnitude in a cell line panel) with the most potent example exhibiting IC50S in the pM range. Cytotoxicity correlated with the ability of the compounds to cross-link naked DNA. Cross-linking was also observed in living cells, at much lower concentrations than for a related symmetrical PBD dimer. A thermal cleavage assay was used to assess sequence selectivity, demonstrating that the CBI portion controlled the alkylation sites, while the PBD substituent increased the overall efficiency of alkylation. Several compounds were tested for in vivo activity using a tumor growth delay assay against WiDr human colon carcinoma xenografts, with one compound (the most cytotoxic and most efficient cross-linker) showing a statistically significant increase in survival time following a single iv dose.

  DOI：

  10.1021/jm020526p

文献信息

• 5-HTX MODULATORS
  申请人：Klaveness Jo

  公开号：US20090029979A1

  公开（公告）日：2009-01-29

  This invention relates to compounds which bind to serotonin receptors inside or outside the central nervous system, in particular compounds which bind to the 5-HT 2 or 5-HT 7 receptors, their preparation and use, compositions containing them, and methods of treatment using them.

  本发明涉及与中枢神经系统内或外的血清素受体结合的化合物，特别是与5-HT2或5-HT7受体结合的化合物，其制备和使用，包含它们的组合物以及使用它们的治疗方法。
• Modulators of Preripheral 5-Ht Receptors
  申请人：Klaveness Jo

  公开号：US20070254874A1

  公开（公告）日：2007-11-01

  Novel modulators of 5-HT4 receptors have been developed which have a selectivity for peripheral receptors rather than those of the central nervous systems. Theses include novel derivatives of known modulators as well as entirely novel entities. Surprisingly, the derivatised compounds of the known modulators maintain a high binding affinity to 5-HT4 receptors, despite the presence of an acidic moiety at the end of an optional chain. The entirely novel entities also exhibit good binding affinity to 5-HT4 receptors. All of the compounds of the invention have a common motif which includes a basic nitrogen moiety and an acidic moiety. The compounds of the invention, due at least in part to their high ionisation potential at physiological pH, have the unique properties of selectively for peripheral 5HT4 receptors over those of the CNS, good binding affinity, and selectively of 5HT4 receptors over other serotonin receptors.

  已经开发出了5-HT4受体的新型调节剂，其选择性针对的是外周受体而非中枢神经系统受体。其中包括已知调节剂的新型衍生物以及全新的实体。令人惊讶的是，已知调节剂的衍生物化合物尽管在可选链的末端存在酸性基团，但仍保持对5-HT4受体的高结合亲和力。全新的实体也表现出良好的5-HT4受体结合亲和力。发明中的所有化合物都具有一个共同的基团，其中包括一种碱性氮基团和一种酸性基团。该发明中的化合物，至少部分原因是由于它们在生理pH值下具有高离化电位，具有选择性地作用于外周5-HT4受体而非中枢神经系统受体，具有良好的结合亲和力，并且对5-HT4受体的选择性高于其他血清素受体。
• [EN] MODULATORS OF PERIPHERAL 5-HT RECEPTORS<br/>[FR] MODULATEURS DE RECEPTEURS PERIPHERIQUES 5-HT
  申请人：BIO MEDISINSK INNOVASJON AS

  公开号：WO2005061483A3

  公开（公告）日：2005-10-27
• WO2007/7072
  申请人：——

  公开号：——

  公开（公告）日：——
• MODULATORS OF PERIPHERAL 5-HT RECEPTORS
  申请人：Serodus AS

  公开号：EP1701951B1

  公开（公告）日：2010-02-10